Мы используем файлы cookie для корректной работы сайта и улучшения вашего опыта. Продолжая пользоваться сайтом, вы соглашаетесь с их использованием.
Для размещения заказа оставьте ваш номер телефона. Мы с вами свяжемся в ближайшее время
In 2020, Rapid Bio was the first in Russia to register and launch the production of COVID-19 rapid tests.
Today, the company has already brought more than 25 diagnostic products to market, with more than 90 still in development.
We develop test systems for laboratory and rapid diagnostics, microfluidic devices, and solutions based on NGS sequencing.
Development of rapid tests for bedside diagnostics
Areas of Work
Development of test systems for laboratory diagnostics
Conducting clinical trials
Scientific and educational activities
German Khunteev
Science Director
The work of the R&D team is based on a scientific approach to developing the best solutions for the in vitro diagnostics market in strict compliance with Russian and international standards.
We are actively working on many projects to introduce new technological approaches into everyday medical practice.
We are confident that the Russian scientific and practical school is capable of creating and implementing products that set the standard on the global market.
We are confident that the Russian scientific and practical school is capable of creating and implementing products that set the standard on the global market.
On the International Stage
Rapid Bio was the first in Russia to register its test in Europe, successfully completed registrations in Thailand and Myanmar, is undergoing the registration process, and is actively developing the markets of Tanzania and South Africa with HIV and malaria solutions.
Video About Us
From a small team of bioengineers to recognized industry experts — watch the video about how Rapid Bio develops and manufactures world-class test systems.
